주요 논문
3
*2026년 기준 최근 6년 이내 논문에 한해 Impact Factor가 표기됩니다.
1
article
|
인용수 0
·
2025P3.12.68 Regulating Autophagy Will Be a Potential Key Point in Overcoming EGFR TKI Resistance in Non-Small Cell Lung Cancer
Hee-Jin Jang, Sung Soo Kim, Joo Hyeong Oh, Jae‐Heon Kang
Journal of Thoracic Oncology
https://doi.org/10.1016/j.jtho.2025.09.930
Autophagy
Lung cancer
Key (lock)
Cancer
Cell
Drug resistance
2
article
|
인용수 0
·
2025P2.08.44 Adverse Cardiovascular Events Related to Immune Checkpoint Inhibitors in Staging IB-IIIb Non-Small Cell Lung Cancer: A Real-World Study
Jae‐Heon Kang, Lei Jiang, Jun Chen, Hui Ma, W-Z. Zhong
Journal of Thoracic Oncology
https://doi.org/10.1016/j.jtho.2025.09.678
Adverse effect
Programmed cell death 1
Lung
Immune system
Nivolumab
Lung cancer
Immune checkpoint
3
article
|
인용수 0
·
2022154TiP AdvanTIG-204: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus anti-PD-1 mAb tislelizumab (TIS) plus concurrent chemoradiotherapy (cCRT) in patients (pts) with untreated limited-stage small cell lung cancer (LS-SCLC)
Yi-Chang Lu, Youling Gong, Jae‐Heon Kang, J. Whan Ree, X. Chen, Xiao Lin, J. Zhang, Hossein Borghaei
IF 50.5 (2022)
Annals of Oncology
https://doi.org/10.1016/j.annonc.2022.02.185
Medicine
Monoclonal antibody
Chemoradiotherapy
TIGIT
Monoclonal
Antibody
Oncology
Cancer research
Immunology
Internal medicine